Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Françoise Brun-Vézinet

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Virologie (Montrouge, France)|January 9, 2020
Antiretroviral treatments in 2012: improvements and future prospectsCharlotte Charpentier, Véronique Joly, Patrick Yeni, et al.
AIDS Research and Human Retroviruses|September 16, 2008
Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central AfricaMélanie Caron, Maria Makuwa, Sandrine Souquière, et al.
Antiviral Therapy|February 22, 2007
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimenDiane Descamps, Mounir Ait-Khaled, Charles Craig, et al.
HIV Clinical Trials|August 2, 2006
Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trialsPhilippe Flandre, Claire Pinçon, Jean-Pierre Aboulker, et al.
Antiviral Therapy|September 6, 2002
Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trialPhilippe Flandre, Gilles Peytavin, Vincent Meiffredy, et al.
Journal of Clinical Microbiology|December 8, 2004
Rapid discrimination between human immunodeficiency virus type 2 groups A and B by real-time PCRJean-Christophe Plantier, Marie Gueudin, Fabienne de Oliveira, et al.
Antiviral Therapy|April 26, 2003
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen receivedPhilippe Flandre, Diane Descamps, Veronique Joly, et al.
AIDS (London, England)|April 11, 2006
No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohortDiane Descamps, Florence Damond, Antoine Bénard, et al.
Journal of Virology|July 15, 2005
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021)Christophe Delaunay, Françoise Brun-Vézinet, Roland Landman, et al.
AIDS Research and Human Retroviruses|July 10, 2004
Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classificationFlorence Damond, Michael Worobey, Pauline Campa, et al.
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Virologie (Montrouge, France)|January 9, 2020
Antiretroviral treatments in 2012: improvements and future prospectsCharlotte Charpentier, Véronique Joly, Patrick Yeni, et al.
AIDS Research and Human Retroviruses|September 16, 2008
Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central AfricaMélanie Caron, Maria Makuwa, Sandrine Souquière, et al.
Antiviral Therapy|February 22, 2007
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimenDiane Descamps, Mounir Ait-Khaled, Charles Craig, et al.
HIV Clinical Trials|August 2, 2006
Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trialsPhilippe Flandre, Claire Pinçon, Jean-Pierre Aboulker, et al.
Antiviral Therapy|September 6, 2002
Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trialPhilippe Flandre, Gilles Peytavin, Vincent Meiffredy, et al.
Journal of Clinical Microbiology|December 8, 2004
Rapid discrimination between human immunodeficiency virus type 2 groups A and B by real-time PCRJean-Christophe Plantier, Marie Gueudin, Fabienne de Oliveira, et al.
Antiviral Therapy|April 26, 2003
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen receivedPhilippe Flandre, Diane Descamps, Veronique Joly, et al.
AIDS (London, England)|April 11, 2006
No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohortDiane Descamps, Florence Damond, Antoine Bénard, et al.
Journal of Virology|July 15, 2005
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021)Christophe Delaunay, Françoise Brun-Vézinet, Roland Landman, et al.
AIDS Research and Human Retroviruses|July 10, 2004
Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classificationFlorence Damond, Michael Worobey, Pauline Campa, et al.
Pageof 8